(Q85678153)

English

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

scientific article published on 01 October 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Frederick J Raal

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Narimon Honarpour

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Dirk J Blom

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

G Kees Hovingh

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Feng Xu

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Scott M Wasserman

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Evan A Stein

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

TESLA Investigators

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

0 references

publication date

1 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

385

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

9965

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

341-350

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular genetics of the LDL receptor gene in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommendations for the use of LDL apheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Lipoprotein(a) in homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961374-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(14)61374-X

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25282520%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q85678153&oldid=2041797103"